REG - PureTech Health PLC - Director/PDMR Shareholding

Puretech HealthAnnouncement

27/06/2024 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240627:nRSa2103Ua&default-theme=true

RNS Number : 2103U  PureTech Health PLC  27 June 2024

27 June 2024

PureTech Health plc

 

PDMR Notifications

 

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to giving life to new classes
of medicine to change the lives of patients with devastating diseases,
announces the sale of certain shares by members of executive management and
non-executive directors ("PDMRs") pursuant to its recently completed Tender
Offer.

The Company's total issued ordinary share capital is 257,927,489 shares,
18,608,909 shares of which are held in treasury by the Company.

PDMR Notification

 

The information contained in the below notification is disclosed in accordance
with Article 19 of the EU Market Abuse Regulation.

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Eric Elenko

                                                                  John LaMattina

                                                                  Robert Langer

 2   Reason for the notification
 a)  Position/status                                              Eric Elenko: President
                                                                  John LaMattina: Non-Executive Director
                                                                  Robert Langer: Non-Executive Director
 b)  Initial notification/Amendment                               Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         PureTech Health plc
 b)  LEI                                                          213800LVPDNO2Z9T9I39
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of PureTech Health plc

                                                                  ISIN GB00BY2Z0H74
 b)  Nature of the transaction                                    Sale of ordinary shares pursuant to Company's recently completed Tender Offer.
 c)  Price(s) and volume(s)                                       Individual      Price     Volume
                                                                  Eric Elenko     2.50 GBP  479,553 ordinary shares
                                                                  John LaMattina  2.50 GBP  54,882 ordinary shares
                                                                  Robert Langer   2.50 GBP  233,098 ordinary shares
 e)  Date of the transaction                                      24 June 2024
 f)  Place of the transaction                                     London Stock Exchange (XLON)

b)

Nature of the transaction

Sale of ordinary shares pursuant to Company's recently completed Tender Offer.

c)

Price(s) and volume(s)

 Individual      Price     Volume
 Eric Elenko     2.50 GBP  479,553 ordinary shares
 John LaMattina  2.50 GBP  54,882 ordinary shares
 Robert Langer   2.50 GBP  233,098 ordinary shares

e)

Date of the transaction

24 June 2024

f)

Place of the transaction

London Stock Exchange (XLON)

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and European
marketing authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates were
initially identified or discovered and then advanced by the PureTech team
through key validation points.

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHXDLFLZQLEBBL